UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended February 28, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-9610 Commission file number: 001-15136 Carnival Corporation Carnival plc (Exact name of registrant as specified in its chart ...

FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended February 28, 2025 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-9610 Commission file number: 001-15136 Carnival Corporation Carnival plc (Exact name of registrant as specified in its chart ...

Financial Position - As of December 31, 2024, Genelux Corporation estimates its cash, cash equivalents, and short-term investments to be approximately $30.9 million[4]. - The Company has not yet completed its financial close process for the quarter and year ended December 31, 2024, and the preliminary cash estimate is subject to change[4]. - The corporate presentation made available on March 25, 2025, includes forward-looking statements regarding the Company's financial position and clinical trial outcomes[5]. Clinical Trials - In a Phase 1b clinical trial, 71% of evaluable participants (5 out of 7) achieved disease control with Olvi-Vec immunochemotherapy, showing tumor reductions ranging from 24% to 79%[11]. - The FDA indicated that a clinically meaningful progression-free survival advantage could support traditional approval for Olvi-Vec in treating platinum-resistant/refractory ovarian cancer[12]. - The Company anticipates reporting interim results from the Phase 2 VIRO-25 trial in the second half of 2025[14]. - Topline results from the Phase 3 OnPrime/GOG-3076 trial are expected to be reported in the first half of 2026[13]. - Treatment-related adverse events in the Olvi-Vec trial were mostly mild to moderate, with no maximum tolerated dose reached to date[8]. - The Company plans to provide an interim readout of updated data from the ongoing clinical trial in the second half of 2025[10]. - The FDA recommended a pre-BLA meeting to discuss next steps following the completion of the trial[12].

Revenue Performance - Revenue for Q4 2024 increased by 1% to $5.8 million compared to $5.76 million in Q4 2023[6] - Full year 2024 total revenue was $23.057 million, a 6% decrease from $24.522 million in 2023[11] - For the three months ended December 31, 2024, the company reported revenues of $5,826,000, a slight increase from $5,762,000 in the same period of 2023[29] Profitability and Loss - Adjusted EBITDA for Q4 2024 was $871,000, representing 15% of revenue, up from a loss of $(27,000) in Q4 2023[7] - Net loss from continuing operations for Q4 2024 was $(10.945) million, or $(2.85) per diluted share, compared to a net loss of $(1.512) million, or $(0.40) per diluted share in Q4 2023[7] - Operating loss for the full year 2024 was $(16.319) million, compared to $(2.739) million in 2023, primarily due to a $14.15 million impairment loss[11] - The company reported a net loss from continuing operations of $(13,281,000) for the year ended December 31, 2024, compared to $(3,441,000) in 2023, indicating a worsening loss situation[29] - The company reported a net loss of $10,793 million for the year ended December 31, 2024, compared to a net income of $766 million in 2023[32] Cash Flow and Financial Health - Cash flow from operations improved to $353,000 in Q4 2024 from $(236,000) in Q4 2023[6] - The net cash provided by operating activities for the full year ended December 31, 2024, was $400,000, a significant improvement from a cash used of $(741,000) in 2023[17] - The adjusted free cash flow for the full year ended December 31, 2024, was $26,000, compared to $(476,000) in 2023, reflecting a positive turnaround[17] - Net cash provided by operating activities from discontinued operations was $2,760 million, down from $3,801 million in 2023[32] - Total cash and cash equivalents at the end of the period were $4,103 million, a decrease from $5,714 million at the beginning of the year[32] Asset and Liability Management - Total assets decreased from $65,152,000 in 2023 to $50,638,000 in 2024, a decline of approximately 22.3%[26] - The company's total liabilities decreased from $29,732,000 in 2023 to $25,412,000 in 2024, a reduction of about 14.5%[26] Customer Metrics - Subscription customers increased to 1,124 in Q4 2024 from 1,053 in Q4 2023[6] - Annual recurring revenue (ARR) for subscriptions reached $10.735 million, up from $9.489 million at the end of 2023[11] Impairment and Investments - The company incurred an impairment loss on intangible assets of $14,150,000 for the three months ended December 31, 2024, compared to no such loss in the same period of 2023[29] - The company incurred a loss on impairment of intangible assets amounting to $14,150 million, indicating potential challenges in asset valuation[32] - Capitalized software expenditures rose to $597 million, compared to $478 million in 2023, reflecting ongoing investment in technology[32] Strategic Outlook - The company aims to optimize capital allocation and increase customer counts and market share moving forward[4] - The company expects to continue to award stock in exchange for services, but the amount of stock-based compensation is excluded from certain adjustments due to its variability[1] - The company did not make any acquisitions during the year, as indicated by the absence of cash outflows for business purchases[32]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 | | | Name of each exchange | | --- | --- | --- | | Title of each class | Trading Symbol(s) | on which registered | | Class A common stock, par value $0.0001 | RUM | The Nasdaq Global Market | | per share | | | | Warrants to purchase one share of Class A | RUMBW | The Nasdaq Global Market | | common stock | | | Securities registered pursuan ...

Financial Performance - Revenue for Q4 2024 was $30.2 million, an increase of 48% compared to $20.4 million in Q4 2023[4] - Net loss for Q4 2024 was $236.8 million, compared to a loss of $29.3 million in Q4 2023, primarily due to a $184.7 million loss in derivative expense related to Tether's investment[4] - Adjusted EBITDA loss improved by $16.6 million to $13.4 million in Q4 2024 compared to Q4 2023[4] - Revenues for the three months ended December 31, 2024, increased to $30,228,287, compared to $20,391,872 for the same period in 2023, representing a growth of 48.5%[31] - Total expenses for the year ended December 31, 2024, were $226,341,761, up from $216,510,463 in 2023, reflecting an increase of 4%[31] - The net loss for the year ended December 31, 2024, was $(338,362,779), compared to a net loss of $(116,420,462) in 2023, indicating a significant increase in losses[36] - The company reported a loss per share of $(1.66) for the year ended December 31, 2024, compared to $(0.58) in 2023[31] - Adjusted EBITDA for the year ended December 31, 2024, was $(92,069,864), an improvement from $(115,332,549) in 2023[39] - The company incurred share-based compensation expenses totaling $23,814,763 for the year ended December 31, 2024, compared to $16,134,714 in 2023, an increase of 47.5%[39] User Metrics - Average Monthly Active Users (MAUs) reached 68 million, with 52 million from the U.S. and Canada, representing a 21% sequential growth[4] - Average Revenue Per User (ARPU) increased by 18% to $0.39 in Q4 2024 from $0.33 in Q3 2024[4] - Average Revenue Per User (ARPU) is calculated quarterly as Audience Monetization revenue divided by MAUs, excluding Other Initiatives revenue[22] Strategic Investments and Initiatives - Rumble received a strategic investment of $775 million from Tether, including $250 million in gross proceeds to strengthen its balance sheet[4][6] - Rumble's Board approved a $20 million strategy to diversify corporate treasury into Bitcoin, reflecting its belief in cryptocurrency[6] - The company announced a cloud services agreement with the Government of El Salvador, indicating market expansion efforts[6] Financial Position - Rumble's cash, cash equivalents, and marketable securities totaled approximately $114 million as of December 31, 2024[4] - Cash and cash equivalents decreased to $114,018,900 as of December 31, 2024, down from $218,338,658 in 2023, a decline of 47.8%[33] - The accounts receivable increased to $9,778,941 as of December 31, 2024, from $5,440,447 in 2023, representing an increase of 80.5%[33] Risks and Challenges - Forward-looking statements indicate potential risks including competition, user growth sustainability, and the impact of economic factors on advertising revenue[26] - Rumble's cloud services business operates in a highly regulated environment, which may affect its financial performance and operational capabilities[27] - The company has identified a material weakness in internal control over financial reporting as of December 31, 2024, which could impact the accuracy of financial reporting[27] - The company is exposed to risks associated with its recently implemented Bitcoin treasury strategy, which may affect its financial condition[26] - Rumble's reliance on third-party data for performance metrics may lead to reputational risks if inaccuracies are perceived[27] Infrastructure and Operational Focus - Rumble is focused on creating an independent infrastructure for a high-growth video platform and cloud services, aiming to restore the internet to its roots[23] - The company uses Adjusted EBITDA as a non-GAAP financial measure to evaluate core operating performance, which excludes various expenses such as interest, taxes, and share-based compensation[24] Transition and Methodology Changes - As of July 1, 2023, the transition from Universal Analytics (UA) to Google Analytics 4 (GA4) has occurred, impacting the calculation of Monthly Active Users (MAUs) and making comparisons between the two methodologies challenging[21]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39069 Aprea Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 84-2246769 (State or other jurisdictio ...

Drug Development and Clinical Trials - Aprea Therapeutics is advancing its WEE1 inhibitor, APR-1051, which has shown a 29.4% overall response rate (ORR) in a Phase 2 study for recurrent uterine serous carcinoma[16]. - The company is currently enrolling the fourth cohort in a Phase 1 study for APR-1051, with safety and efficacy data expected in H1 2025[6]. - Aprea's ATR inhibitor, ATRN-119, is in a Phase 1/2a study, with data readout anticipated in H2 2025[6]. - The clinical study for ACESOT-1051 is enrolling up to 79 patients, focusing on advanced solid tumors with specific gene alterations[40]. - The ongoing study for ATRN-119 aims to establish a maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) with a total enrollment of up to 132 patients[62]. - The study design for ATRN-119 includes a dose escalation phase with up to 72 patients, followed by a dose expansion phase[62]. - Aprea Therapeutics is conducting ongoing Phase 1/2a clinical studies for ATRN-119, with preliminary signs of clinical benefit observed at low doses[74]. Drug Safety and Efficacy - Aprea's WEE1 inhibitor has demonstrated minimal off-target effects, preserving hematologic safety profiles in clinical trials[6]. - APR-1051 has shown negligible inhibition of hERG channels, suggesting a low risk of QT prolongation at effective doses[29]. - APR-1051 has been reported to be safe and well-tolerated, with no hematologic toxicity observed in preclinical studies[48]. - No serious adverse events (SAE) or Grade 4 adverse events related to ATRN-119 were reported, with the most common adverse events being Grade 1 and Grade 2[71]. - ATRN-119 is potentially differentiated from other ATR inhibitors in selectivity and toxicity profile, providing continuous tumor suppression[74]. Financial Position and Funding - Aprea Therapeutics reported cash and equivalents of approximately $22.8 million as of December 31, 2024[77]. - The company closed a private placement of common stock in March 2024, raising approximately $16.0 million, with potential additional funds of up to $18.0 million from warrant exercises[77]. - Aprea Therapeutics is financed into Q4 2025, with near-term catalysts expected from ongoing clinical trials[81]. Strategic Goals and Market Positioning - The company aims to identify lead candidates for its discovery platform by 2024, focusing on optimizing drug development[6]. - Aprea's clinical pipeline includes multiple anticipated milestones from 2024 to 2026, indicating a robust development strategy[7]. - The company emphasizes the need for highly efficient WEE1 inhibitors with improved safety profiles, addressing significant unmet medical needs in oncology[16]. - The company is focused on expanding its market presence through innovative therapies that address critical gaps in cancer treatment[5]. - Aprea Therapeutics has a strong intellectual property portfolio, including four issued US patents protecting lead molecules and analogs[76]. - The company aims to achieve short-term inflection points and evaluate optimal strategic partnerships in the oncology space[81]. - The company has opportunities in various cancers, including ovarian, colorectal, prostate, and breast cancers, with both single-agent and combination therapies being explored[81]. Drug Characteristics and Performance - APR-1051 demonstrated a Cmax of 1,460 ng/ml at a dose of 10 mg/kg/day, indicating potentially favorable drug exposure compared to competitors[28]. - In preclinical studies, APR-1051 showed a tumor volume reduction in OVCAR-3 xenograft models, with significant suppression of tumor growth[32]. - ATRN-119 exhibits near-dose proportional exposure following oral administration, with a Tmax of approximately 2 hours and a half-life estimated between 4-6 hours[68][74]. - APR-1051 is being developed as a best-in-class WEE1 inhibitor, targeting specific cancer-associated gene alterations[47]. - ATRN-119 is positioned as a potentially best-in-class oral ATR inhibitor, with continuous daily dosing being evaluated[55].

Financial Performance - Energy Focus reported net sales of $4.86 million in 2024, a decrease of 15% compared to $5.72 million in 2023, primarily due to a 16% decline in MMM product sales and a 13% decline in commercial sales [185]. - The gross profit for 2024 was $0.7 million, or 14% of net sales, compared to $0.2 million, or 4% of net sales in 2023, driven by a decrease in fixed and variable costs [188]. - Net loss for 2024 was $1.6 million, a significant improvement from a net loss of $4.3 million in 2023, primarily due to reduced costs [200]. - Net cash used in operating activities was $1.3 million in 2024, improved from $2.4 million in 2023, reflecting better cash management despite ongoing losses [206][207]. - Cash provided by financing activities was $0.1 million in 2024, significantly lower than $4.5 million in 2023, primarily due to reduced stock issuance proceeds [209][210]. Cost Management - Operating expenses decreased significantly from 73.4% of net sales in 2023 to 52.3% in 2024, with selling, general, and administrative expenses dropping from $3.6 million to $2.0 million [184][192]. - The company has undertaken significant cost-cutting measures in 2023 and 2024 to address operational expenses while maintaining customer satisfaction [172]. - The company aggressively reduced its workforce and operating expenses throughout 2023 and into 2024 to manage fixed costs [204]. Debt and Financial Position - The company achieved a gain of $187,000 on debt extinguishment in 2024, related to the early termination of the 2022 Streeterville Note, compared to no such gain in 2023 [194]. - Energy Focus has eliminated all external high-interest debt, improving its financial position and supporting business expansion plans [174]. - As of December 31, 2024, the company had $0.6 million in cash, down from $2.0 million at the end of 2023, with an accumulated deficit of $154.9 million [201][205]. Revenue Challenges - The military maritime (MMM) business faced challenges in 2024 due to delays in government funding and long sales cycles, impacting revenue recognition [174]. - Two major customers accounted for approximately 33% of net sales for the twelve months ended December 31, 2024, indicating a concentration risk [201]. Growth Strategies - The company is focusing on developing new product lines, including Energy Storage Systems (ESS) and GaN Power Supplies, to enhance its market position [175]. - The company plans to achieve profitability by launching new products, including Redcap® emergency battery backup tubular TLEDs, and exploring GaN-based power supply circuitry [203]. - Energy Focus is actively seeking additional external funding to support its growth strategies and initiatives [176]. - The company continues to seek external funding alternatives to support its growth strategies and initiatives [204]. Tax and Valuation - The effective tax rate for both 2024 and 2023 was 0%, with a full valuation allowance recorded against deferred tax assets due to net operating losses [197][198]. Inventory and Commitments - The company has approximately $0.3 million in outstanding purchase commitments for inventory as of December 31, 2024, with 88% related to a single party [212]. Investing Activities - The cash used in investing activities was $19 thousand in 2024, primarily for property and equipment acquisitions, down from $69 thousand in 2023 [208].

Revenue and Profit - Revenue for the year ended December 31, 2024 was $43.5 million, compared to $0 for the same period in 2023, reflecting the launch of DefenCath[210]. - Gross profit for the year ended December 31, 2024 was $40.3 million, with a cost of revenue of $3.2 million[209][211]. - For the year ended December 31, 2024, the company achieved revenue of $31.2 million in the fourth quarter, a significant increase compared to $11.5 million in the third quarter and $0.8 million in the second quarter[219]. - The company reported a net income of $12.9 million in the fourth quarter, contrasting with a net loss of $3.3 million in the third quarter and a loss of $15.3 million in the second quarter[219]. Expenses - Research and development expenses decreased by 70% to $3.9 million for the year ended December 31, 2024, down from $13.2 million in 2023[212]. - Selling and marketing expenses increased by 59% to $28.7 million for the year ended December 31, 2024, compared to $18.1 million in 2023[213]. - General and administrative expenses rose by 69% to $30.0 million for the year ended December 31, 2024, up from $17.7 million in 2023[214]. Losses - The loss from operations for the year ended December 31, 2024 was $22.4 million, a 54% decrease from the loss of $49.0 million in 2023[209]. - The net loss for the year ended December 31, 2024 was $17.9 million, a 61% decrease from the net loss of $46.3 million in 2023[209]. Product Information - DefenCath is the first and only FDA-approved antimicrobial catheter lock solution in the U.S., shown to reduce the risk of CRBSI by up to 71% in clinical studies[194]. - DefenCath received NTAP reimbursement of 75% of the wholesaler acquisition cost per hospital stay, with a potential maximum NTAP of $3,656.10[193]. - The company estimates that up to 100,000 HD-CVC placements occur each year, with pass-through status providing separate reimbursement under Medicare for DefenCath[197]. Cash Flow and Investments - The company generated net cash used in operating activities of $50.6 million for the year ended December 31, 2024, an increase of $12.2 million from $38.4 million in 2023[222]. - Net cash provided by investing activities was $21.2 million for the year ended December 31, 2024, compared to a net cash used of $17.1 million in 2023[223]. - The company had total cash, cash equivalents, and short-term investments of $51.7 million as of December 31, 2024, down from $76.0 million in 2023[225]. Future Expectations and Agreements - The company expects to continue funding operations through cash collections and capital raising sources, which may be dilutive to existing stockholders[226]. - A three-year agreement with Syneos Health Commercial Services was entered into in December 2024, committing the company to a minimum of $9.6 million for promoting DefenCath[230]. - The company anticipates payment of $2 million in net sales milestones in 2025 under the ND License Agreement with ND Partners, LLP[231]. - The company received $1.4 million from the sale of unused New Jersey net operating losses in March 2024, contributing to its tax benefit[221]. - The company has $30.2 million of common stock available for potential sale under the ATM program as of December 31, 2024[225].